[
  {
    "ts": "2026-01-15T04:13:06+00:00",
    "headline": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
    "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
      "content": {
        "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
        "contentType": "STORY",
        "title": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
        "description": "",
        "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
        "pubDate": "2026-01-15T04:13:06Z",
        "displayTime": "2026-01-15T04:13:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m9hRgcHsaxFnPMapF7dREg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y6HX0lxrpZR4ULhZqw1OVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-novo-nordisk-reshapes-strategy-041306688.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T04:04:58+00:00",
    "headline": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
    "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
      "content": {
        "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
        "contentType": "STORY",
        "title": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
        "description": "",
        "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
        "pubDate": "2026-01-15T04:04:58Z",
        "displayTime": "2026-01-15T04:04:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L91cjHFSZBMXC6h1bBPvVA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ShFiCgASkTfyaCE7q2Kwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-eli-lilly-enters-2026-040458178.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T12:41:27+00:00",
    "headline": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
    "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
    "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "3453a452-44b3-3569-bd87-656c622f9743",
      "content": {
        "id": "3453a452-44b3-3569-bd87-656c622f9743",
        "contentType": "STORY",
        "title": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
        "description": "",
        "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
        "pubDate": "2026-01-15T12:41:27Z",
        "displayTime": "2026-01-15T12:41:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "IRON"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T13:28:05+00:00",
    "headline": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
    "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
    "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a68628fd-ff52-3af1-8f30-7e0cfbbbd78f",
      "content": {
        "id": "a68628fd-ff52-3af1-8f30-7e0cfbbbd78f",
        "contentType": "STORY",
        "title": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
        "description": "",
        "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
        "pubDate": "2026-01-15T13:28:05Z",
        "displayTime": "2026-01-15T13:28:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b",
          "originalWidth": 1280,
          "originalHeight": 851,
          "caption": "Top 5 Ivy League Colleges for Pre-Med",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PnKMb7f0mnBhgN0lpEiLOQ--~B/aD04NTE7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b.cf.webp",
              "width": 1280,
              "height": 851,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XUQ9vqZSV6.Y0ANGHO0RlA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T14:41:59+00:00",
    "headline": "JPM26: Eli Lilly’s obesity drugs target commercial and governmental access",
    "summary": "Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-obesity-drugs/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "edb1acdb-8592-3bbe-b842-a211e9c8b028",
      "content": {
        "id": "edb1acdb-8592-3bbe-b842-a211e9c8b028",
        "contentType": "STORY",
        "title": "JPM26: Eli Lilly’s obesity drugs target commercial and governmental access",
        "description": "",
        "summary": "Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.",
        "pubDate": "2026-01-15T14:41:59Z",
        "displayTime": "2026-01-15T14:41:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/7f5c962059c0cf2651c79d980523e734",
          "originalWidth": 1000,
          "originalHeight": 542,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ArN6HCAKIIo6lPtD7nApiA--~B/aD01NDI7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/7f5c962059c0cf2651c79d980523e734.cf.webp",
              "width": 1000,
              "height": 542,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XdzhN44Fpp2LUip329zBZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/7f5c962059c0cf2651c79d980523e734.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-obesity-drugs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-eli-lilly-obesity-drugs-144159992.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T14:35:53+00:00",
    "headline": "Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch",
    "summary": "Investing.com -- UBS raised its 12-month price target for Novo Nordisk to 390 from 295 Danish crowns, citing valuation factors and investor attention ahead of the launch of the Wegovy weight-loss pill. The bank reiterated a Neutral rating on the stock.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-stock-target-raised-143553715.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "7ab37732-b461-3065-b32e-0f9747496b44",
      "content": {
        "id": "7ab37732-b461-3065-b32e-0f9747496b44",
        "contentType": "STORY",
        "title": "Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch",
        "description": "",
        "summary": "Investing.com -- UBS raised its 12-month price target for Novo Nordisk to 390 from 295 Danish crowns, citing valuation factors and investor attention ahead of the launch of the Wegovy weight-loss pill. The bank reiterated a Neutral rating on the stock.",
        "pubDate": "2026-01-15T14:35:53Z",
        "displayTime": "2026-01-15T14:35:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-target-raised-143553715.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-target-raised-143553715.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T13:26:00+00:00",
    "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
    "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
    "url": "https://finance.yahoo.com/news/why-mercks-32-rally-isnt-132600400.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a911c0d6-f243-3a37-9c98-9829b23a873a",
      "content": {
        "id": "a911c0d6-f243-3a37-9c98-9829b23a873a",
        "contentType": "STORY",
        "title": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
        "description": "",
        "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
        "pubDate": "2026-01-15T13:26:00Z",
        "displayTime": "2026-01-15T13:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-mercks-32-rally-isnt-132600400.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-mercks-32-rally-isnt-132600400.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T15:15:07+00:00",
    "headline": "JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus",
    "summary": "Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.",
    "url": "https://www.clinicaltrialsarena.com/analyst-comment/jpm26-eli-lilly-lpa-drugs/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "c9085830-8df8-39d1-b821-fe952df6d68a",
      "content": {
        "id": "c9085830-8df8-39d1-b821-fe952df6d68a",
        "contentType": "STORY",
        "title": "JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus",
        "description": "",
        "summary": "Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.",
        "pubDate": "2026-01-15T15:15:07Z",
        "displayTime": "2026-01-15T15:15:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/9082cf8beb55009c7901a73f7da72d44",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "The initiative will also engage current joint programmes such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center. Credit: Tada Images / Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bb0k.tnjn3L9bFpLqUtycw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/9082cf8beb55009c7901a73f7da72d44.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D.4xbTSq3l3uIpjXTg5G9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/9082cf8beb55009c7901a73f7da72d44.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/analyst-comment/jpm26-eli-lilly-lpa-drugs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-eli-lilly-highlights-lp-151507272.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T16:39:49+00:00",
    "headline": "Where is Eli Lilly and Company (LLY) Headed According to Analysts?",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, Jefferies reaffirmed a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,300.00. The rating update came after Eli Lilly and Company (NYSE:LLY) announced on January 8 […]",
    "url": "https://finance.yahoo.com/news/where-eli-lilly-company-lly-163949755.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e6ca21f2-8e18-39e3-a68d-b72501e481b4",
      "content": {
        "id": "e6ca21f2-8e18-39e3-a68d-b72501e481b4",
        "contentType": "STORY",
        "title": "Where is Eli Lilly and Company (LLY) Headed According to Analysts?",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, Jefferies reaffirmed a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,300.00. The rating update came after Eli Lilly and Company (NYSE:LLY) announced on January 8 […]",
        "pubDate": "2026-01-15T16:39:49Z",
        "displayTime": "2026-01-15T16:39:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-eli-lilly-company-lly-163949755.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-eli-lilly-company-lly-163949755.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T15:17:00+00:00",
    "headline": "How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?",
    "summary": "Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.",
    "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-llys-151700049.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3e9d0721-7826-3188-861a-5d98762a9903",
      "content": {
        "id": "3e9d0721-7826-3188-861a-5d98762a9903",
        "contentType": "STORY",
        "title": "How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?",
        "description": "",
        "summary": "Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.",
        "pubDate": "2026-01-15T15:17:00Z",
        "displayTime": "2026-01-15T15:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-llys-151700049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-llys-151700049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]